PMID- 29254882
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20180924
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 254
DP  - 2018 Mar 1
TI  - The impact of delayed treatment on 6-minute walk distance test in patients with 
      pulmonary arterial hypertension: A meta-analysis.
PG  - 299-301
LID - S0167-5273(17)35421-9 [pii]
LID - 10.1016/j.ijcard.2017.12.016 [doi]
AB  - BACKGROUND: The impact of treatment delay in stable patients with pulmonary 
      arterial hypertension (PAH) remains unaddressed. METHODS: This meta-analysis 
      included six datasets of PAH therapies with randomized-controlled trials (RCT) 
      and corresponding open-label extension (OLE) studies. We evaluated the change in 
      6MWD at 1year in the OLE studies by active treatment versus ex-placebo group. The 
      ex-placebo group (i.e., the patients randomized to placebo in the RCT and 
      ultimately treated with active therapy in the OLE) represented the 
      "delay-in-treatment" population. RESULTS: Patients with a treatment delay of 
      12-16weeks in PAH targeted therapy had an improvement in 6-minute walk distance 
      (6MWD) test at 1year, but this improvement did not amount to the same degree of 
      improvement as their initially treated counterparts. The difference in 6MWD was 
      15m to 20m at 1year. CONCLUSION: A short-term delay in PAH targeted therapy may 
      adversely affect functional capacity in patients with PAH. This meta-analysis 
      provides some insight as to whether earlier treatment would benefit stable 
      patients with PAH.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Vizza, Carmine Dario
AU  - Vizza CD
AD  - Department of Cardiovascular and Respiratory Disease, University of Rome La 
      Sapienza, Rome, Italy. Electronic address: dario.vizza@uniroma1.it.
FAU - Badagliacca, Roberto
AU  - Badagliacca R
AD  - Department of Cardiovascular and Respiratory Disease, University of Rome La 
      Sapienza, Rome, Italy.
FAU - Messick, Chad R
AU  - Messick CR
AD  - United Therapeutics Corp, Research Triangle Park, NC, USA.
FAU - Rao, Youlan
AU  - Rao Y
AD  - United Therapeutics Corp, Research Triangle Park, NC, USA.
FAU - Nelsen, Andrew C
AU  - Nelsen AC
AD  - United Therapeutics Corp, Research Triangle Park, NC, USA.
FAU - Benza, Raymond L
AU  - Benza RL
AD  - The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20171214
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
SB  - IM
MH  - Exercise Test/methods/*trends
MH  - Humans
MH  - Hypertension, Pulmonary/diagnosis/*physiopathology/*therapy
MH  - Randomized Controlled Trials as Topic/methods
MH  - Time-to-Treatment/*trends
MH  - Treatment Outcome
MH  - Walking/*physiology
OTO - NOTNLM
OT  - 6-minute walk distance
OT  - Delayed treatment
OT  - Early treatment
OT  - Functional capacity
OT  - Pulmonary arterial hypertension
EDAT- 2017/12/20 06:00
MHDA- 2018/09/25 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/09/01 00:00 [received]
PHST- 2017/11/16 00:00 [revised]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - S0167-5273(17)35421-9 [pii]
AID - 10.1016/j.ijcard.2017.12.016 [doi]
PST - ppublish
SO  - Int J Cardiol. 2018 Mar 1;254:299-301. doi: 10.1016/j.ijcard.2017.12.016. Epub 
      2017 Dec 14.